Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01044745 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
A Phase 2 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01044745 is a Phase 2 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 20 participants.
The verdict
NCT01044745, a Phase 2 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, rituximab, together with anti-thymocyte globulin, tacrolimus, and mycophenolate mofetil before and after the transplant may stop this from happening
Interventions
- DRUG tacrolimus
- PROCEDURE allogeneic hematopoietic stem cell transplantation
- DRUG rituximab
- DRUG mycophenolate mofetil
- DRUG anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-12-10 |
| Est. Completion | 2017-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01044745
The ClinicalTrials.gov registry entry for NCT01044745 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which tacrolimus is the first listed.
NCT01044745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01044745 about?
NCT01044745 is a clinical study titled "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer". This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer. Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer...
What is the current status of trial NCT01044745?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-12-10. Estimated completion is 2017-10-10.
What interventions are being tested in trial NCT01044745?
The interventions under investigation include: tacrolimus (DRUG), allogeneic hematopoietic stem cell transplantation (PROCEDURE), rituximab (DRUG), mycophenolate mofetil (DRUG), anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT01044745?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.